E.M.C2 Appoints Paolo Cappella Ph.D. as CEO effective April 1, 2019. Dr.Cappella is an expert in the development of innovative non-clinical, clinical and bioanalytical methods aimed at understanding the mechanism of action of new chemical entities. He has nearly 25 years' experience in the areas of non-clinical and clinical pharmacology, oncology and immunology.
Prior to joining EMC2, Dr. Cappella served for nearly 2 years at Flowmetric Europe, in roles of Lab Head and project manager for EU flow cytometry service market. . Prior to this role, Dr. Cappella worked for 15 years at Nerviano Medical Sciences as senior research scientist in B.U. Oncology where he has conducted research on kinase inhibitors, monoclonal antibodies and CART, employing innovative flow cytometry developments in cell cycle analysis, granted Farmindustria Prize at 2009.
Dr. Cappella has authored more than 40 peer reviewed scientific articles including several book chapters and is the holder of one US patent. He holds a Doctorate (Ph.D.) in Cell Biology from the University of Urbino and a Bachelor's degree (BS) in Biology from the Mario Negri Institute